Acrivon Therapeutics (ACRV) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Piper Sandler | Maintained | Overweight | $8.00 from $6.00 | Jan 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $19.00 | Nov 25, 2025 |
| Oppenheimer | Maintained | Outperform | $8.00 from $9.00 | Aug 14, 2025 |
| Jones Trading | Downgraded | Buy → Hold | — | May 16, 2025 |
| Oppenheimer | Maintained | Outperform | $9.00 from $10.00 | May 15, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $19.00 | Mar 28, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $19.00 from $22.00 | Mar 26, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | — | Mar 26, 2025 |
| Citizens Capital Markets | Maintained | Market Outperform | $17.00 | Mar 26, 2025 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Jan 31, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $22.00 | Nov 14, 2024 |
| BMO Capital | Maintained | Outperform | $27.00 from $28.00 | Nov 14, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $22.00 | Sep 16, 2024 |
| BMO Capital | Maintained | Outperform | $28.00 from $25.00 | Sep 16, 2024 |
| Ladenburg Thalmann | Upgraded | Neutral → Buy | $16.00 | Sep 16, 2024 |
| JMP Securities | Maintained | Market Outperform | $17.00 | Sep 16, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $22.00 | Aug 13, 2024 |
| BMO Capital | Maintained | Outperform | $25.00 | May 15, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $22.00 from $20.00 | May 14, 2024 |
| Ladenburg Thalmann | Downgraded | Buy → Neutral | — | Apr 29, 2024 |
Frequently asked questions
Is ACRV a buy, sell, or hold?
Analysts covering Acrivon Therapeutics currently average a Buy rating: 6 buy, 0 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on ACRV?
On Jan 9, 2026, Piper Sandler maintained Acrivon Therapeutics at Overweight with a price target of $8.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.